Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

Lianyungang Runzhong Pharmaceutical Co., Ltd., part of Sino Biopharmaceutical Ltd., is a Chinese company located in Lianyungang that manufactures pharmaceutical products.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Beijing Sailintai Pharmaceutical Technology Co., Ltd., established on 2006-07-05, Business scope includes technology development,Technical Services,technical consulting,Technology Promotion,technology transfer;Medical Research and Experimental Development;Sell ​​self-developed products;Import and export,Technology Import and Export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Part of Servier SAS, Servier Pharmaceuticals LLC is an American company located in Boston, MA, that operates as a pharmaceuticals company. It was founded in 1954. David K. Lee is currently the CEO of the firm.\nThe company says this about itself: Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need. As a leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients. Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies.

Sanhome was one of the first group of companies which have been awarded GMP certificate in China. The company has been certificated as ‘state high-tech innovation enterprise’ by China Ministry of Science & Technology in 2003, has been ranked in top 100 pharmaceutical enterprises in China since 2009, and has been awarded ‘Top 100 pharmaceutical enterprises’ and ‘Top 50 pharmaceutical enterprises in growth’ by All-China Federation of Industry & Commerce in 2015.

Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to the R&D and manufacturing of National Class A new medicines with independent IPR. Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders in 2003, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to diseases severely influencing human health, e.g. malignant tumors, diabetes, and cardio-cerebrovascular disease. Its headquarters is located at Yuhang Economic and Technological Development Zone, Hangzhou City, with a pharmaceutical R&D center established in Beijing and Hangzhou respectively. At present, it boasts a team of nearly 1,000 employees, in which there are dozens of returned PhD holders with five of them included in The Recruitment Program of Global Experts of China. On Nov. 7th, 2016, Betta Pharmaceuticals was successfully listed in GEM of Shenzhen Stock Exchange. Betta has over 20 new drug development projects currently, among which its flagship product, Icotinib Hydrochloride (Conmana), has created several records: in Jul. 2012, it was involved in The International Annual Report on New Drug Research and Development, as the first targeted anti-cancer drug made in China; in Aug. 2013, Lancet Oncol, a world leading medical magazine, published a full text of China’s clinical research achievement of innovative drugs for the first time and commended that “Icotinib Hydrochloride has created the new era of China’s R&D of anti-cancer drugs”, according to the Editor’s Note; the compound and crystal form patents of Icotinib Hydrochloride won the Golden Prize of China Patent Award in 2012 and 2014 respectively; the R&D and industrialized achievement of Icotinib Hydrochloride won the First Prize of 2015 National Prize for Progress in Science and Technology, as the first time that this award was won by China’s chemical pharmaceutical industry and Zhejiang enterprise; in 2016, Icotinib Hydrochloride (Conmana) won the highest award of China’s industrial area, China Grand Award for Industry. The Company possesses over 100 authorized patents with other hundreds of patents applied in process; sets 4 technical standards, in which the standard for Icotinib Hydrochloride crude drugs and tablets has turned into national standard; won national special award of Key Formulation of New Drugs for several times and was involved in MOST National High-tech R&D Program (863 Program), China Torch Program and National Strategic Innovative Product. Independent R&D, strategic cooperation and marketing are the three driving factors promoting the better and faster development of Betta, laying a solid foundation for the realization of its strategic vision of “turning into a transnational pharmaceutical enterprise headquartered in China”. Innovation is of no bounds. Betta Pharmaceuticals will continue to carry forward its development concept as pioneering innovation to the benefit of the public, devote itself to innovation for the public and technology development benefiting the public by means of development of new medicines, to provide Chinese residents with more affordable medicines of good quality.

Shouyao Holdings (Beijing) Co. Ltd. engages in the clinical research stage of the innovative drug business. The company is mainly involved in the research and development of drugs covering non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, leukemia, key tumor indications, and type 2 diabetes. It offers a collection of AI drug design, medicinal chemistry, biology, pharmacokinetics, toxicology, pharmaceutical research, clinical research, operation management, and quality management. The company was founded on April 19, 2016 and is headquartered in Beijing, China.

Teligene was established in 2011. It is a high-tech pharmaceutical research and development company focusing on the research and development and industrialization of small molecule innovative drugs. The company's senior technical management team is experienced and familiar with cutting-edge drug development technologies and development trends at home and abroad. The company mainly aims to research and develop hot spots and develop trends of new international small molecule targeted anti-tumor drugs, and designs, screens, optimizes and develops original small molecule targeted anti-tumor drugs with independent intellectual property rights.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Takara Bio Inc., develops, manufactures, and distributes a wide range of life science reagents and kits under the Takara®, Clontech®, and Cellartis® brands. Key products include SMART® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART library construction kits; the innovative In-Fusion® cloning system; Guide-it™ gene editing tools; Tet-based inducible gene expression systems; and Living Colors® fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi, gene editing, and stem cell studies; and plant and food research

Takara Shuzo Co. Ltd. manufactures and markets alcoholic beverages. Its products include alcoholic beverages, raw alcohol, health drinks, and seasonings. The company was founded in 1925 and is headquartered in Kyoto, Japan.

PANAGENE Inc. engages in the molecular diagnostics business. It develops, manufactures and sells peptide nucleic acid (PNA) genetic diagnostic chips. The firm operates through the PNA Materials and Diagnostic Product business divisions. Its products are marketed as PANAMutyper, PNAClamp, PANArray, PANA qPCR, PNA Oligo and Monomer. The company was founded on April 16, 2001 and is headquartered in Daejeon, South Korea.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

Ming Chi Biotechnology (Shanghai) Co., Ltd., established on 2020-04-21, Business scope includes general items:Biological Technology,medical technology,Technical services in the field of medical technology,technology development,technical consulting,technology transfer;Engineering and Technology Research and Experimental Development;internet data service;Medical Research and Experimental Development;Technology guidance;Retailing of computer software, hardware and auxiliary equipment;Sales of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).